Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Absci To Host December 11 Seminar On ABS-201 For Androgenetic Alopecia; Phase 1/2a Trial Now Expected To Begin In December, Ahead Of Prior Guidance

Author: Benzinga Newsdesk | October 15, 2025 08:08am

Webinar on December 11 to feature leading KOLs in dermatology and hair loss alongside Absci leadership

Phase 1/2a trial now expected to begin in December 2025, ahead of prior guidance

VANCOUVER, Wash. and NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Absci (NASDAQ:ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced the company will host a virtual seminar on December 11, 2025 at 10:00am ET focused on the company's ABS-201 (anti-PRLR) program for androgenetic alopecia.

Additionally, Absci now expects to initiate the Phase 1/2a trial for this program in early December, ahead of prior guidance for early 2026, with an interim efficacy readout anticipated in the second half of 2026. The seminar to be hosted on December 11 will feature leading KOLs in the dermatology and hair loss fields, and highlight the clinical trial path, differentiated profile, and market potential of the ABS-201 program.

Posted In: ABSI

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist